Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | P2RX1 | P51575 | 9/20 | 0.73 |
| ▸ | TMPRSS4 | Q9NRS4 | 8/20 | 0.65 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.62 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.62 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18341044 | 0.86 | P2RX1 (0.77) | MEN1KMT2AP2RX1TMPRSS4P2RX4 | |
| SCHEMBL25349531 | 0.85 | MEN1 (0.65) | MEN1KMT2AP2RX1TMPRSS4P2RX4 | |
| SCHEMBL29454776 | 0.85 | P2RX1 (1.00) | MEN1KMT2AP2RX1TMPRSS4P2RX4 | |
| SCHEMBL2169619 | 0.85 | P2RX1 (1.00) | MEN1KMT2AP2RX1TMPRSS4P2RX4 | |
| SCHEMBL30692663 | 0.85 | MEN1 (1.00) | MEN1KMT2AKCNMA1ALDH1A1HPGD | |
| SCHEMBL24438159 | 0.85 | MEN1 (1.00) | MEN1KMT2AKCNMA1ALDH1A1HPGD | |
| SCHEMBL18290068 | 0.84 | P2RX1 (0.80) | MEN1KMT2AP2RX1TMPRSS4P2RX4 | |
| SCHEMBL9609313 | 0.84 | MEN1 (0.53) | MEN1KMT2AP2RX1TMPRSS4P2RX4 | |
| SCHEMBL14363286 | 0.84 | PLAU (0.69) | MEN1KMT2AP2RX1TMPRSS4ALDH1A1 | |
| SCHEMBL10272282 | 0.84 | P2RX1 (0.79) | MEN1KMT2AP2RX1TMPRSS4P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406831-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-12-21 | — | — | US | disclosed |
| EP-4243799-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | The Trustees of Indiana University (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022103572-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022103572-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-05-19 | — | — | WO | disclosed |
| US-8148328-B2 | Salicylanilides enhance oral delivery of therapeutic peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-28 | — | — | US | disclosed |
| US-20090163408-A1 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163408-A1 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | DNPEP, NGLY1, VIP | MEN1 3158/4885KMT2A 3301/4885P2RX1 3156/4885 |
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | DNPEP, PTMS, NGLY1 | MEN1 1625/4885KMT2A 2123/4885P2RX1 4373/4885 |
| US-20230406831-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | HSP90B1, HSPBP1, HSP90AB1 | MEN1 4702/4885KMT2A 4732/4885P2RX1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.